 LAWRENCEVILLE, N.J., March 12, 2021 GLOBE NEWSWIRE -- Celsion Corporation NASDAQ: CLSN, a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Friday, March 19, 2021 to discuss financial results for the year ended December 31, 2020 and provide an update on clinical development programs with GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin under investigator-sponsored development for several cancer indications. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines. The Companys immunotherapy candidate, GEN-1, is currently in Phase II development for the localized treatment of advanced ovarian cancer. 